References
- Guillemin F, Saraux A, Guggenbuhl P et al. Prevalence of rheumatoid arthritis in France: 2001. Ann. Rheum. Dis. 64(10), 1427–1430 (2005).
- Maravic M, Le Bihan C, Boissier MC, Landais P. Activité rhumatologique hospitalière à partir des données PMSI 2000 – Etude de six affections rhumatologiques. Rev. Rheum. 71(12), 1221–1225 (2004).
- Maravic M, Daurès JP, Sany J. Hospital costs of rheumatoid arthritis in France in 2001. Ann. Rheum. Dis. 64(SupplIII, abs), 403 (2005).
- Maravic M, Daurès JP, Sany J. L’évaluation medico-économique de la polyarthrite rhumatoïde en France. J. Eco. Med. 23(2), 116–121 (2005).
- Maravic M, Bozonnat MC, Sevezan A et al. Preliminary evaluation of medical outcomes (including quality of life) and costs in incident RA cases receiving hospital-based multidisciplinary management. Joint Bone Spine 67(5), 425–433 (2000).
- Sany J, Bourgeois P, Saraux A et al. Characteristics of patients with rheumatoid arthritis (RA) in France: a study of 1109 patients managed by hospital-based rheumatologists. Ann. Rheum. Dis. 63(10), 1235–1240 (2004).
- Guillemin F, Durieux S, Daurès JP et al. Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists. J. Rheumatol. 31(7), 1297–1304 (2004).
- Fautrel B, Woronoff-Lemsi MC, Ethgen M et al. Impact of medical practices on the costs of management of rheumatoid arthritis by antiTNFα biological therapy in France. Joint Bone Spine 72(6), 550–556 (2005).
- Maravic M, Daurès JP, Sany J. Comparaison des coûts médicaux directs de la prise en charge de la polyarthrite rhumatoïde avec les nouvelles biothérapies pendant 53 semaines en 2004. Rev. Rheum. 71(10–11), 1019 (2004).
- Maravic M, Bergé C, Daurès JP, Boissier MC. Survey of practices regarding of early typical rheumatoid arthritis by rheumatologists in France. Clin. Exp. Rheumatol. 22(3), 319–327 (2004).
- Maravic M, Bergé C, Daurès JP, Boissier MC. Practices for management of flare of a long-standing rheumatoid arthritis: survey among French rheumatologists. Clin. Exp. Rheumatol. 23(1), 36–42 (2005).
- Fautrel B, Saraux A, Maillefert JF et al. Costs of workups of the diagnosis of early arthritis: results of a nationwide survey. Arthritis Care Res. 51(4), 507–512 (2004).
- Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis. Arthritis Rheum. 42(6), 1209–1218 (1999).
- Clarke AE, Levinton X, Joseph L et al. Predicting the short-term direct medical costs incurred by patients with rheumatoid arthritis. J. Rheumatol. 26(5), 1068–1075 (1999).
- Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis. A three-year study of 7,527 patients. Arthritis Rheum. 48(10), 2750–2762 (2003).
- Grabiel S, Drummond M, Maetzel A et al. Omeract 6 – economics working group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J. Rheumatol. 30(4), 886–890 (2003).
Website
- Collèges des économistes de la santé. French guidelines for the economic evaluation of healthcare technologies; September 2004. www.cesasso.org/docs/France_Guidelines_HE_Evaluation.PDF